共 50 条
- [41] Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterationsJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Moreno, VictorLoriot, YohannValderrama, Begona PerezBeato, CarmenVano, Yann-AlexandreFleming, Mark T.Duran, IgnacioSiena, SalvatoreTolbert, Jaszianne A.OHagan, AnneAkapame, SydneyLau, Yvonne Y.Geoffrois, LionnelTagawa, Scott T.Mellado, BegonaSiefker-Radtke, Arlene O.
- [42] Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK plus non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Campelo, Rosario GarciaLin, Huamao MarkPerol, MauriceJahanzeb, MohammadPopat, SanjayZhu, YanyanZhang, PingkuanCamidge, D. Ross
- [43] Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12Harbeck, NadiaFranke, FabioVillanueva-Vazquez, RafaelLu, Yen-ShenTripathy, DebuChow, LouisBabu, Govind K.Im, Young-HyuckChandiwana, DavidGaur, AnilLanoue, BradRodriguez-Lorenc, KarenBardia, Aditya
- [44] Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trialCANCER RESEARCH, 2018, 78 (13)Chung, Hyun CheolArkenau, Hendrik-TobiasLee, JeeyunRha, Sun YoungOh, Do-YounWyrwicz, LucjanKang, Yoon-KooLee, Keun-WookBauer, Todd M.Lee, Sung SookKemeny, MargaretKeilholz, UlrichMelichar, BohuslavMita, AlainPlummer, RuthSmith, DenisGelb, Arnold B.Xiong, HuilingHong, JanetChand, VikramSafran, Howard
- [45] First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma A randomized, double-blind Phase-3-Study Comparing the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) versus Pembrolizumab and Placebo as First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma who are not suitable for a Cisplatin-based Therapy and whose Tumors express PD-L1, as well as for Patients who are not suitable for a platinum-based Therapy regardless of the PD-L1-Expression (LEAP-011-AB 68/18 of the AUO)AKTUELLE UROLOGIE, 2021, 52 (01) : 28 - 29Rexer, H.Retz, M.Kramer, M.
- [46] Phase II study of GEN-001 in combination with avelumab in patients with PD-L1-positive locally advanced, or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) who have progressed after second-line (2L) and beyond (GEN001-201 study)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 368 - 368Lee, JeeyunJung, MinkyuLee, Keun-WookRyu, Min-HeeKwon, MinsukPark, Kyung MiYoon, Young-KwangKim, MincheolPark, Hansoo
- [47] Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)Journal of Gastrointestinal Cancer, 2015, 46 (2) : 109 - 117Bodoky G.Scheulen M.E.Rivera F.Jassem J.Carrato A.Moiseyenko V.Vynnychenko I.Prausová J.Van Laethem J.-L.Cascinu S.Ajani J.A.
- [48] Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pre-treated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Lara, Primo N., Jr.Kroll, StewChatzkel, Jonathan AlexanderTeoh, Deanna Gek KoonMa, Vincent T.Kilari, DeepakHwang, ClaraSweis, Randy F.Yalamanchili, KiranPeguero, Julio AntonioLi, TianhongParikh, Mamta
- [49] An open, randomized Phase-III Study with MK6482 versus Everolimus in Participants with advanced Renal Cell Cancer showing Tumor Progression after previous PD-1/L1 and VEGF-targeted Therapies (HIF-005) - AUO No. AN 51/19 Study on the Third- or Fourth Line-Therapy for Patients with non-resectable locally advanced or metastatic Renal Cell CancerAKTUELLE UROLOGIE, 2021, 52 (04) : 318 - 319Rexer, HeidrunDe Santis, MariaDoehn, Christian
- [50] Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialLANCET ONCOLOGY, 2018, 19 (08): : 1126 - 1134Friedlander, MichaelGebski, ValGibbs, EmmaDavies, LucyBloomfield, RalphHilpert, FelixWenzel, Lari B.Eek, DanielRodrigues, ManuelClamp, AndrewPenson, Richard T.Provencher, DianeKorach, JacobHuzarski, TomaszVidal, LauraSalutari, VandaScott, ClareNicoletto, Maria OrnellaTamura, KenjiEspinoza, DavidJoly, FlorencePujade-Lauraine, Eric